

Supplementary Materials

Liver fibrosis and diabetic peripheral neuropathy in individuals with type 2 diabetes mellitus: an observational, cross-sectional study

**Eleonora Zanni¹, Silvia Coluccia¹, Stefano Boni¹, Massimiliano Colzani¹, Roberta Sueri¹,
Simonetta Lugari², Cristina Felicani², Fabio Nascimbeni², Carla Greco^{1,3}**

¹Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy.

²Unit of Internal and Metabolic Medicine, Civil Hospital of Baggiovara, A. O. U. of Modena and University of Modena and Reggio Emilia, Modena 41126, Italy.

³Unit of Endocrinology, Department of Medical Specialties, Azienda Ospedaliero-Universitaria Di Modena, Ospedale Civile Di Baggiovara, Modena 41126, Italy.

Correspondence to: Dr. Carla Greco, Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy. E-mail: carlagreco@unimore.it

Supplementary Table 1. General, biochemical and therapeutical information of 86 subjects with type 2 diabetes mellitus and hepatic steatosis

	Overall (<i>n</i> = 86)
General characteristics	
Hip circumference (cm)	112.49 ± 15.64 (85-155)
Previous or current smoking (%)	60 (69.80)
Physical activity (%)	16 (18.6)
Biochemical evaluations	
Fasting glucose (mg/dl)	147.86 ± 44.72 (73-306)
AST (U/L)	29.17 ± 20.01 (12-128)
ALT (U/L)	32.02 ± 20.78 (8-132)
γ-GT (U/L)	48.75 ± 53.07 (8-345)
Albumin (g/dl)	4.13 ± 0.32 (3.29-4.80)
Total cholesterol (mg/dl)	156.04 ± 46.91 (76-270)
HDL (mg/dl)	44.92 ± 11.28 (18-79)
LDL (mg/dl)	92.26 ± 36.66 (33-191)
Triglycerides (mg/dl)	156.39 ± 87.04 (49-507)
Therapy	
antihypertensive therapy (%)	67 (77.9)
antidyslipidemic therapy (%)	76 (88.4)
insulin therapy (%)	10 (11.6)
mixed (insulin + no-insulin) antidiabetic therapy (%)	16 (18.6)
no-insulin antidiabetic therapy (%)	63 (73.3)
Metformin (%)	69 (80.2)
Pioglitazone (%)	0
Acarbose (%)	0
SU (%)	0
DPPIVi (%)	6 (7)
GLP1Ra (%)	46 (53.5)
SGLT2i (%)	27 (31.4)

ALT: Alanine aminotransferase; AST: aspartate aminotransferase; DPPIVi: dipeptidyl peptidase-4 inhibitors; γ-GT: gamma-glutamyl transferase; GLP1Ra: glucagon-like peptide-1 receptor agonist; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SGLT2i: sodium-glucose cotransporter 2 inhibitor; SU: sulfonylureas.

Supplementary Table 2. Clinical and characteristics ad biohumoral assessments in subjects with and without diabetic peripheral neuropathy

	no-DPN (<i>n</i> = 49)	DPN (<i>n</i> = 37)	<i>P</i>
General and anthropometric characteristics			
Hip circumference (cm)	115.71 ± 16.25	108.63 ± 14.20	0.062
Previous or current smoking (%)	37 (75.5)	23 (62.2)	0.182
Physical activity (%)	10 (20.4)	6 (16.2)	0.621
Biochemical evaluations			
Fasting glucose (mg/dl)	142.78 ± 41.22	154.59 ± 48.74	0.227
AST (U/L)	29.54 ± 19.37	28.67 ± 21.10	0.875
ALT (U/L)	34.94 ± 24.25	28.14 ± 14.41	0.139
γ-GT (U/L)	44.64 ± 39.32	54.53 ± 68.21	0.424
Total cholesterol (mg/dl)	148.27 ± 48.69	167.00 ± 42.58	0.075
HDL cholesterol (mg/dl)	43.08 ± 11.47	47.43 ± 10.66	0.083
LDL cholesterol (mg/dl)	88.34 ± 36.69	98.15 ± 36.40	0.244
Triglycerides (mg/dl)	150.58 ± 73.70	164.34 ± 103.20	0.480

ALT: Alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; DPN: diabetic peripheral neuropathy; eGFR: estimated glomerular filtration rate; HbA1c: glycated haemoglobin; γ-GT: gamma-glutamyl transferase; HDL: high-density lipoprotein; LDL: low-density lipoprotein.

Supplementary Table 3. Anti-diabetic treatment according to the clinical diagnosis of diabetic peripheral neuropathy

	no-DPN	DPN	<i>P</i>
	(<i>n</i> = 49)	(<i>n</i> = 37)	
Therapy			
With antihypertensive therapy (%)	35 (71.4)	32 (86.5)	0.096
With antidyslipidemic therapy (%)	41 (83.7)	35 (94.6)	0.118
With no-insulin antidiabetic therapy (%)	38 (77.6)	25 (67.6)	0.300
With mixed (insulin + no-insulin) antidiabetic therapy (%)	8 (16.3)	8 (21.6)	0.532
With insulin therapy (%)	5 (10.2)	5 (13.5)	0.635

DPN: Diabetic peripheral neuropathy.